PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
https://doi.org/10.21294/1814-4861-2017-16-6-100-104
Abstract
Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. For well differentiated NET, it has been shown that an increase in VEGF expression is associated with metastasis and decrease in progression-free survival.
About the Authors
G. S. Emelianova
Moscow State University of Medicine and Dentistry, Moscow
Russian Federation
Russian Federation
Lecturer, Department of Oncology
SPIN-code: 7407-1472
N. F. Orel
N.N. Blokhin Russian Cancer Research Center, Moscow;
Russian Medical Academy of Continued Professional Education, Moscow
Russian Federation
Russian Federation
MD, Leading Researcher, Chemotherapy Department
SPIN-code: 9304-7931.
V. A. Gorbunova
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, Leading Researcher, Chemotherapy Department
AuthorID: 1403082
A. A. Kolomeytseva
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, Leading Researcher, Chemotherapy Department
SPIN-code: 1893-8316
A. A. Kuznetsova
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
MD, postgraduate, Chemotherapy Department
Russian Federation
MD, postgraduate, Chemotherapy Department
A. E. Kuzminov
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Researcher, Department of Clinical Biotechnologies
Russian Federation
Researcher, Department of Clinical Biotechnologies
A. A. Fedenko
N.N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Russian Federation
MD, Head of Chemotherapy Department
SPIN-code: 9487-7668
References
1. Zhang J., Jia Z., Li Q., Wang L., Rashid A., Zhu Z., Evans D.B., Vauthey J.N., Xie K., Yao J.C. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007 Apr 15; 109 (8): 14708–86.
2. Koumarianou A., Kaltsas G. Bevacizumab Plus Temozolomide: A Novel Treatment Option for Advanced Neuroendocrine Tumors? J Clin Oncol. 2013 Mar 1; 31 (7): 975–6. doi: 10.1200/JCO.2012.45.7523.
3. Chan J.A., Stuart K., Earle C.C., Clark J.W., Bhargava P., Miksad R., Blaszkowsky L., Enzinger P.C., Meyerhardt J.A., Zheng H., Fuchs C.S., Kulke M.H. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30 (24): 2963–8. doi: 10.1200/JCO.2011.40.3147.
4. Yao J.C., Phan A., Hoff P.M., Chen H.X., Charnsangavej C., Yeung S.C., Hess K., Ng C., Abbruzzese J.L., Ajani J.A. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26 (8): 1316–23. doi: 10.1200/JCO.2007.13.6374.
5. Berruti A., Fazio N., Ferrero A., Brizzi M.P., Volante M., Nobili E., Tozzi L., Bodei L., Torta M., D’Avolio A., Priola A.M., Birocco N., Amoroso V., Biasco G., Papotti M., Dogliotti L. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic wellto-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer. 2014 Mar 14; 14: 184. doi: 10.1186/1471-2407-14-184.
6. Mitry E., Walter T., Baudin E., Kurtz J.E., Ruszniewski P., Dominguez-Tinajero S., Bengrine-Lefevre L., Cadiot G., Dromain C., Farace F., Rougier P., Ducreux M. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – a phase II non-randomised trial. Eur J Cancer. 2014 Dec; 50 (18): 3107–15. doi: 10.1016/j.ejca.2014.10.001.
7. Abstracts of the 13th Annual ENETS Сonference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2016 March 9–11; Barcelona, Spain.
Review
For citations:
Emelianova G.S., Orel N.F., Gorbunova V.A., Kolomeytseva A.A., Kuznetsova A.A., Kuzminov A.E., Fedenko A.A. PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT. Siberian journal of oncology. 2017;16(6):100-104. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-6-100-104
Views:
847
Email this article 
